Poladova L. R.
COMPARATIVE EVALUATION OF THE EFFECTIVENESS OF PATHOGENETIC AND ETIOLOGICAL TREATMENT OF OTOMYCOSIS
Show/Download
About the author:
Poladova L. R.
Heading:
CLINICAL AND EXPERIMENTAL MEDICINE
Type of article:
Scientific article
Annotation:
According to WHO, every fifth inhabitant of the Earth has a fungal disease. Under these conditions, given the constant risk of immunosuppression caused by one reason or another, everyone can become a target for the defeat and subsequent generalization of fungal infection. In this regard, timely treatment and prevention of mycoses is of particular relevance. In 2022, WHO published for the first time a list of the 19 most dangerous fungal pathogens that pose a threat to public health. Most of them are also pathogens of otomycosis. WHO has declared the search for ways to block the spread of these pathogens, as well as to prevent the emergence of resistance to antifungal drugs, to be priority areas of medicine. Most of these pathogens can be pathogens of otomycosis. The purpose of our study was to identify the most common pathogens of otomycosis in Azerbaijan, to study their sensitivity to antifungal to evaluate the effectiveness of pathogenetic treatment of otomycosis with a drug with a keratolytic effect, compared with antfungal drugs that contribute to the development of resistance in fungal pathogens.
Tags:
Bibliography:
- Parums D. Editorial: The World Health Organization (WHO) Fungal Priority Pathogens List in Response to Emerging Fungal Pathogens During the COVID-19 Pandemic. Medical science monitor. 2022;28:e939088. DOI: 10.12659/MSM.939088.
- Denning D. Calling upon all public health mycologists: To accompany the country burden papers from 14 countries. European journal of clinical microbiology & infectious diseases. 2017;36(6):923–924.
- Vennewald I, Klemm E. Otomycosis: Diagnosis and treatment. Clinics in dermatology. 2010;28(2):202–211.
- Anwar K, Gohar M. Otomycosis: clinical features, predisposing factors and treatment implications. Pakistan journal of medical sciences. 2014;30(3):564–567.
- Kiakojuri K, Rajabnia R, Mahdavi Omran S, Pournajaf A, Karami M, Taghizadeh Armaki M. Role of Clotrimazole in Prevention of Recurrent Otomycosis. Bio Med research international. 2019;2019:5269535. DOI: 10.1155/2019/5269535.
- Gharaghani M, Halvaeezadeh M, Ali Jalaee G, Taghipour S, Kiasat N, Zarei Mahmoudabadi A. Antifungal susceptibility profiles of otomycosis etiological agents in Ahvaz, Iran. Current medical mycology. 2020;6(2):18–22.
- Baumgartner B, Rakita R, Backous D. Scedosporium apiospermum otomycosis. American journal of otolaryngology. 2007;28(4):254–256.
- Abastabar M, Haghani I, Ahangarkani F, Rezai MS, Taghizadeh Armaki M, Roodgari S, et al. Candida auris otomycosis in Iran and review
- Mofatteh MR, Naseripour Yazdi Z, Yousefi M, Namaei MH. Comparison of the recovery rate of otomycosis using betadine and clotrimazole topical treatment. Braz J Otorhinolaryngol. 2018;84(4):404-409.
- Chen Q, Chu H, Tao Y, Peng L, Zhou L, Liu L, et al. A Comparison of Triamcinolone Acetonide Econazole Cream and Nystatin Suspension in Treatment of Otomycosis. Laryngoscope. 2021;131(5):E1640-E1646.
- Gülüstan F, Abakay MA, Demir E. Efficacy of topical isoconazole nitrate in the treatment of otomycosis. Am J Otolaryngol. 2021;42(4):102961.
- Romsaithong S, Tomanakan K, Tangsawad W, Thanaviratananich S. Effectiveness of 3 per cent boric acid in 70 per cent alcohol versus 1 per cent clotrimazole solution in otomycosis patients: a randomised, controlled trial. J Laryngol Otol. 2016;130(9):811-815.
Publication of the article:
«Bulletin of problems biology and medicine», 2023 Issue 4, 171, 232-236 pages, index UDC 6214-037-126
